The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
Study Type
OBSERVATIONAL
Enrollment
505
As per product label
Local Institution - 0001
Seoul, South Korea
WITHDRAWNNovotech Laboratory Korea Co., Ltd.
Seoul, South Korea
RECRUITINGNumber of participants with adverse events (AEs)
Time frame: Up to 24 weeks from treatment initiation
Number of participants with adverse drug reactions (ADRs)
Time frame: Up to 24 weeks from treatment initiation
Number of participants with serious adverse events (SAEs)
Time frame: Up to 24 weeks from treatment initiation
Number of participants with serious adverse drug reactions (SADRs)
Time frame: Up to 24 weeks from treatment initiation
Number of participants with unexpected adverse events (AEs)
Time frame: Up to 24 weeks from treatment initiation
Number of participants with unexpected adverse drug reactions (ADRs)
Time frame: Up to 24 weeks from treatment initiation
Number of participants with unexpected serious adverse events (SAEs)
Time frame: Up to 24 weeks from treatment initiation
Number of participants with unexpected serious adverse drug reactions (SADRs)
Time frame: Up to 24 weeks from treatment initiation
Proportion of participants with static Physician Global Assessment (sPGA) of 0 or 1
Time frame: At Week 16 and/or Week 24 post treatment initiation
Number of participants achieving Psoriasis Area and Severity Index (PASI) 75 (at least a 75% improvement in PASI score from baseline)
First line of the email MUST contain NCT # and Site #.
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: At Week 16 and/or Week 24 post treatment initiation